Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

alpha V beta 8 antagonist PF-06940434

An antagonist of integrin alpha v beta 8, with potential antineoplastic activity. Upon administration, PF-06940434 selectively binds to and blocks the receptor for integrin alpha v beta 8, thereby preventing integrin alpha v beta 8 binding. This may result in the inhibition of cell adhesion in the tumor microenvironment (TME) and blocks the activation of the cytokine transforming growth factor-beta 1 (TGF-b1), preventing TGF-b1-mediated signal transduction. This abrogates TGF-b1-mediated immunosuppression, enhances anti-tumor immunity in the TME and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGF-b1-dependent proliferation of cancer cells. Alpha v beta 8 integrin plays a key role in tumor initiation, growth, and progression through TGF-b1 activation. It is expressed in a variety of tumor cell types and is associated with poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:alpha V beta 8 inhibitor PF-06940434
Code name:PF 06940434
PF-06940434
PF06940434
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search